SciBase Holding AB (DE:5J3)
FRANKFURT:5J3
Want to see DE:5J3 full AI Analyst Report?
5J3 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€48.96M
Enterprise Value€165.56M
Total Cash (Recent Filing)€71.25M
Total Debt (Recent Filing)€23.93M
Price to Earnings (P/E)―
Beta-1.61
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,022,529,970
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€6.39M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelSciBase’s go-to-market includes device placements plus usage-linked consumables and services. That creates durable, repeatable revenue streams that increase lifetime customer value, smooth revenue volatility, and support margin recovery as installed base grows over months.
Strong Top-line GrowthReported revenue growth is robust, reflecting market adoption of diagnostic offerings. Persistent top-line expansion provides the structural runway to scale fixed-cost absorption and improve operating leverage if management sustains commercial execution and converts trials into repeat usage.
Healthy Gross MarginA ~59% TTM gross margin signals strong product-level economics and pricing power in the core diagnostic business. High gross margins give the company room to invest in sales and R&D while preserving a pathway to positive operating income as revenue scales and overheads normalize.
Bears Say
Very Large Operating LossesOperating and net losses massively exceed revenue, indicating the cost base and investment pace are outstripping current commercialization. Without sustained revenue acceleration or structural cost cuts, losses will continue to impede progress toward sustainable profitability over the medium term.
Severe Cash BurnConsistent ~-85M TTM cash outflows show the business is materially cash-consuming. This persistent burn reduces runway, forces reliance on external financing, and constrains the company’s ability to invest opportunistically without raising capital, a structurally important risk.
Financing / Dilution RiskWhile leverage is moderate, equity volatility and deeply negative ROE reflect history of losses and past dilution. Continued operating losses heighten the odds of further equity raises or unfavorable financing, which would dilute shareholders and could constrain strategic autonomy.
SciBase Holding AB News
5J3 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €48.96M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 93 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on May 07, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 1,022,529,970 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―